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Abstract The aim of this study was to describe the type
of risk-reducing gynaecologic surgery (RRGS) and the
extent of pathological evaluation being undertaken for
Australasian women at high familial risk of pelvic serous
cancer. Surgical and pathology reports were reviewed for
women with BRCA1/BRCA2 mutations, or a family history
of breast and ovarian cancer, who underwent RRGS
between 1998 and 2008. ‘‘Adequate’’ surgery was defined
as complete removal of all ovarian and extra-uterine fal-
lopian tube tissue. ‘‘Adequate’’ pathology was defined as
paraffin embedding of all removed ovarian and tubal tissue.
Predictors of adequacy were assessed using logistic
regression. There were 201 women, including 173 mutation
carriers, who underwent RRGS. Of these, 91% had ade-
quate surgery and 23% had adequate pathology. Indepen-
dent predictors of adequate surgery were surgeon type
(OR = 20; 95% CI 2–167; P = 0.005 for gynaecologic
oncologists versus general gynaecologists), more recent
surgery (OR = 1.33/year; 95% CI 1.07–1.67; P = 0.012)
and younger patient age (OR = 0.93/year of age; 95% CI
0.87–0.99; P = 0.028). Independent predictors of adequate
pathology were more recent surgery (OR = 1.26/year;
95% CI 1.06–1.49; P = 0.008) and surgeon type
(OR = 3.1; 95% CI 1.4–6.7; P = 0.004 for gynaecologic
oncologists versus general gynaecologists). Four serous
ovarian cancers and one endometrioid endometrial cancer
were detected during surgery or pathological examination.
In conclusion Australasian women attending a specialist
gynaecologic oncologist for RRGS are most likely to have
adequate surgery and pathological examination. Additional
education of clinicians and consumers is needed to ensure
optimal surgery and pathology in these women.
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Abbreviations
RRGS Risk-reducing gynaecologic surgery
RRSO Risk-reducing salpingo-oophorectomy
kConFab Kathleen Cuningham Foundation
Consortium for Research into Familial
Breast Cancer
RANZCOG Royal Australian and New Zealand College
of Obstetricians and Gynaecologists
DCIS Ductal carcinoma in situ
f/up Follow-up
FDR First degree relative
BC Breast cancer
OC Ovarian cancer
BO Bilateral oophorectomy
TAH-BSO Total abdominal hysterectomy and bilateral
salpingo-oophorectomy
N/A Not available
R Right
L Left
Introduction
Women carrying a mutation in the breast cancer predis-
position genes BRCA1 or BRCA2 have a 40–85% cumu-
lative risk of invasive breast cancer to age 70 and a
15–65% cumulative risk of invasive pelvic serous cancer to
age 70 [1–5]. The term ‘‘pelvic serous cancer’’ is used
because the majority of BRCA1- and BRCA2-associated
gynaecologic cancers appear to originate in the fimbrial
end of the fallopian tube rather than the ovary, although
they resemble, and have typically been labelled as ‘‘serous
ovarian cancer’’ at diagnosis [6]. Women with a family
history of breast and ‘‘ovarian’’ cancer, but no identified
BRCA1 or BRCA2 mutation in the family, are also con-
sidered to be at an elevated risk of pelvic serous cancer [7].
This risk increases as the number of ‘‘ovarian’’ cancer
cases in the family increases [8].
Risk-reducing salpingo-oophorectomy (RRSO) is the
most effective method of reducing pelvic serous cancer risk
in women at high familial risk [9–11] and it is the most
effective means available of decreasing gynaecologic
cancer mortality [12, 13]. In BRCA1 and BRCA2 mutation
carriers RRSO is estimated to reduce the risk of pelvic
serous cancers by 80% and the risk of breast cancer by 50%
[14]. Because there is no adequate screening strategy for
pelvic serous cancers, RRSO is recommended for women
at high familial risk once they have completed child
bearing [15–17].
The recommended risk-reducing surgery involves com-
plete resection of the ovaries and fallopian tubes up to their
insertion into the cornua of the uterus [15, 17–20] as well
as inspection of the peritoneal cavity for macroscopic
evidence of malignancy. Removal of the uterus is optional
and there have been no reports of malignant transformation
in the intramural portion of the fallopian tube when the
uterus has not been removed [21, 22]. Peritoneal lavage is
not routinely recommended for risk-reducing procedures;
however, cytological evaluation of peritoneal washings
may increase the chance of detecting malignancy [12, 23,
24].
There is no universal protocol for the pathological
evaluation of specimens from RRSO. Sectioning and
microscopic examination of both fallopian tubes and ova-
ries in toto by an experienced gynaecological pathologist is
recommended [12, 15–18, 20, 25–27]. There is no uni-
versal recommendation regarding the number of sections
although embedding the ovaries and tubes in their entirety
and cutting at least one section from each 2–3 mm paraffin
block maximises the detection of occult cancer [16, 25, 27,
28]. In mutation carriers up to 85% of the malignancies
detected at RRSO are located in the fallopian tubes,
especially in the fimbria, and complete removal and thor-
ough evaluation of these regions is important [25, 29].
Reported rates for occult malignancy of the ovaries
and/or fallopian tubes following RRSO range from 0.6 to
18.5%. [9, 10, 18, 24, 26, 27, 29–31] This variability may
be due to differences between the studies in terms of
sample size, proportion of mutation carriers in the sample,
age of included women, extent of pathological evaluation
and type of surgery.
We sought to describe the type of surgery and the extent
of pathological evaluation performed in Australasian
BRCA1 and BRCA2 mutation carriers and other women at
high familial risk of ‘‘ovarian cancer’’ who undergo risk-
reducing gynaecologic surgery (RRGS) and to document
the frequency of occult carcinomas.
Patients and methods
Participants were females enrolled in the Kathleen Cun-
ingham Foundation Consortium for Research into Familial
Breast Cancer (kConFab), a resource of data and biospec-
imens from multiple-case breast cancer families [32, 33].
Eligibility criteria are available on the website [32]. Fam-
ilies are recruited via 16 Family Cancer Clinics in Australia
and New Zealand. At enrolment, blood is drawn for pos-
sible future BRCA mutation analysis and epidemiology and
family history questionnaires are completed. A separately
funded and run follow-up study updates cancer events,
epidemiological and lifestyle risk factors and uptake of
preventative strategies on all female participants every
3 years using a mailed self-administered questionnaire
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[34]. Cancer events and surgeries are verified where pos-
sible with pathology and surgical reports. All participants
provide written informed consent and the study has ethics
approval at all recruitment sites.
Women were eligible for the current study if they had:
undergone RRGS after enrolment in kConFab, completed at
least one round of three-yearly follow-up, a documented
deleterious mutation in BRCA1 or BRCA2 or a strong family
history of breast cancer and at least one case of ‘‘ovarian
cancer’’, no personal history of gynaecological cancer and,
both an operation report and a pathology report available
from their surgery. Women with a personal history of breast
cancer, without evidence of distant metastatic disease at the
time of RRGS, were included. Non-carriers within a BRCA1
or BRCA2 mutation-carrying family were excluded.
Date and type of surgery, type of surgeon and macro-
scopic findings at surgery were determined from operation
reports where possible, or from surgical correspondence and
pathology reports. Reason for surgery was determined from
self report by the women and from operation reports. Sur-
geries were performed by the surgeon of the woman’s choice
at multiple sites throughout Australia and New Zealand and
often in institutions not linked with the Family Cancer Centre
that the woman had attended. The term ‘‘adequate’’ was used
to describe surgical procedures where all ovarian and extra-
uterine fallopian tube tissue was completely removed.
For the purposes of this study, we defined surgeon type
as follows: general surgeons were registered fellows of the
Royal Australasian College of Surgeons; general gynae-
cologists were registered fellows of the Royal Australian
and New Zealand College of Obstetricians and Gynaecol-
ogists (RANZCOG); gynaecologic oncologists were
gynaecologists who also held the Certification or Diploma
in Gynaecologic Oncology of the RANZCOG [35].
Details of the pathological evaluation, the presence of
occult cancers and the information communicated from
surgeon to pathologist were abstracted from pathology
reports. The term ‘‘adequate’’ was used to describe patho-
logical examinations where all removed ovarian and tubal
tissue was paraffin embedded. In the absence of a universal
protocol, we did not define a minimum number of sections
to be cut and examined.
New primary gynaecological cancers following RRGS
were self-reported and/or reported by enrolled family
members in the three-yearly follow-up questionnaire and
verified where possible from pathology reports. The dura-
tion of follow-up was calculated from the date of RRGS to
the date of death or last contact.
Statistical analysis
Differences in the proportion of patients receiving adequate
surgery, by surgeon type were tested for using Fisher0s
Exact Test. Odds ratios and their 95% confidence intervals
and associated P-values were estimated by logistic
regression. All multivariable models included age at RRGS
(continuous), year of RRGS (continuous) and surgeon type.
Due to lack of evidence of independent association in the
final multivariable models we did not include as covari-
ables the type of surgery performed (for the evaluation of
adequacy of surgery) and whether or not it was noted in the
pathology request form that the sample was from a woman
at high risk (for the evaluation of adequacy of pathology).
Additional covariates considered for both evaluations were
mutation status (mutation carrier versus non-carrier or
untested), prior personal history of breast cancer and first
degree relatives with ovarian cancer.
All P-values were two sided, and those less than 0.05
were considered statistically significant. All statistical
analyses were carried out using Stata: Release 10 [36].
Results
From February 1998 to March 2008, 403 women enrolled
in kConFab and completing at least one round of follow-
up, had undergone RRGS. Of these, 202 were not eligible
for the present study (135 had no documented gene
mutation and no family history of ovarian cancer; 13 had a
personal history of gynaecological cancer; for 18 an
operation report was not available; 1 had no available
pathology report; 35 were non-carriers within a mutation
carrier family). Characteristics of the remaining 201
women are described in Table 1. There were 102 BRCA1
mutation carriers and 71 BRCA2 mutation carriers.
Tables 2 and 3 summarise the characteristics of the
surgeries and pathological examinations, respectively.
Overall 20% of women had both adequate surgery and
adequate pathological examination. Adequate surgery was
performed in 182 women (91%). The remaining women
had neither fallopian tube (10 women) or only one tube (9
women) removed. General gynaecologists and general
surgeons performed 18 of the 19 inadequate surgeries.
Peritoneal washings were collected in 44 women (22%)
and the cytology was abnormal in one woman who was
diagnosed with ovarian cancer. Based on the pathology
reports, 23% of women had adequate pathological
evaluation.
Tables 4 and 5 present a summary of the characteristics
of the women by the adequacy of surgery and pathology
review, respectively, and the results of univariable and
multivariable analyses exploring the associations between
them. Multivariable analysis confirmed that the indepen-
dent predictors of adequate surgery were surgeon type, year
of surgery and younger patient age. Gynaecologic oncol-
ogists were more likely to perform adequate surgery than
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general gynaecologists (OR = 20; 95% CI 2,167;
P = 0.005) and general surgeons (OR = 89; 95% CI
8,1031; P \ 0.001). Regardless of surgeon type, more
recent surgery was also more likely to be adequate
(OR = 1.33 per year; 95% CI 1.07,1.67; P = 0.012). Only
3 of the 19 inadequate surgeries were performed after 2004.
The independent predictors of adequate pathological
examination were more recent surgery (OR = 1.26; 95%
CI 1.06,1.49; P = 0.008) and surgeon type. Surgeries
Table 1 Characteristics of the 201 participants
Characteristic n (%)a
Year of RRGS
Median [range] 2004 [1998–2008]
1998 4
1999 11
2000 13
2001 19
2002 22
2003 24
2004 38
2005 40
2006 16
2007 13
2008 1
Age at time of RRGS (years)
Median [range] 48 [30–77]
30–39 25 (12)
40–49 93 (46)
50–59 57 (28)
C60 26 (13)
BRCA mutation status
BRCA1 mutation carrier 102 (51)
BRCA2 mutation carrier 71 (35)
No documented mutation (includes untested) 28 (14)
Family history of ovarian cancer
Number of affected first-degree relatives
0 138 (69)
1 58 (29)
[1 5 (2)
Number of affected second-degree relatives
0 134 (67)
1 59 (29)
[1 8 (4)
Prior gynaecological surgery (before RRGS)
None 180 (90)
Unilateral oophorectomy alone 13 (6)
Hysterectomy alone 4 (2)
Unilateral oophorectomy ? hysterectomy 4 (2)
Invasive BC diagnosed before RRGS
Yes 118 (59)
No 83 (41)
Patient reported reason for RRGS
Cancer prevention 189 (94)
To treat breast cancerb 7 (3)
To remove an ovarian/tubal cystc 3 (1)
For cancerd 2 (1)
Table 1 continued
Characteristic n (%)a
Time from RRGS to last f/up or death (months)
Median [range] 35 [0.5–123]
n number, RRGS risk-reducing gynaecologic surgery, DCIS ductal
carcinoma in situ, f/up follow-up
a Unless otherwise indicated
b The surgeon’s intention for these seven women was ovarian cancer
prevention
c The surgeon’s intention for these three women was ovarian cancer
prevention
d These two women had cancer detected at RRGS. The surgeon’s
intention for each was cancer prevention
Table 2 Characteristics of Surgery
Characteristic n (%)
Type of surgery
Laparoscopic 138 (69)
Abdominal 53 (26)
Conversion (laparoscopic [ abdominal) 10 (5)
Hysterectomy at time of RRGS 93 (46)
Surgeon type
Gynaecologic oncologist 105 (52)
General gynaecologist 85 (42)
General surgeon 11 (5)
Adequacy of surgery
Adequate 182 (91)
Not adequatea 19 (9)
Macroscopic abnormality noted at surgery
Yes 5 (2)
Not reported 196 (98)
Peritoneal lavage
Yes 44 (22)
Not reported 157 (78)
n number, RRGS risk-reducing gynaecologic surgery
a Nine women had only one tube removed and 10 women had neither
tube removed
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performed by gynaecologic oncologists were more likely to
be associated with adequate pathology than surgeries per-
formed by general gynaecologists (OR = 3.12; 95% CI
1.4,6.7; P = 0.004).
All women who had a hysterectomy had adequate sur-
gery. There was no difference between abdominal or lap-
aroscopic surgery in terms of adequacy. Clinical notes
provided by the surgeon on the pathology request form,
were included in 188 pathology reports. Of these 80%
documented the woman’s elevated risk for ‘‘ovarian’’
cancer. There was no significant difference between the
three surgeon types in documenting the high risk status.
Although documenting high risk status predicted for ade-
quate pathology in the univariable analysis it was not an
independent predictor of adequate pathology.
Four (2%) pelvic serous cancers were detected at sur-
gery (Table 6). All were in mutation carriers and all were
reported as ovarian in origin although there was little detail
in any about the degree of pathological scrutiny of the
fallopian tubes. Tubal carcinoma in situ was not reported in
any of the 201 cases. The youngest age at cancer diagnosis
was 40 years in a BRCA1 mutation carrier. One
endometrioid adenocarcinoma of the uterus was diagnosed
in a woman with no documented genetic mutation but a
past history of breast cancer and tamoxifen-related post-
menopausal bleeding.
During the follow-up period (median 35 months) one
peritoneal adenocarcinoma was reported in a 70-year-old
BRCA1 mutation carrier, 8 years after RRGS. She had
undergone adequate surgery but inadequate pathological
examination. Six deaths were reported during follow-up
and all were attributed to metastatic breast cancer.
Discussion
This prospective study of RRGS in Australasian women at
high familial and genetic risk for pelvic serous cancer has
revealed the majority had adequate surgery, the minority
had adequate pathological evaluation, and the detection
rate for occult cancers (2%) was relatively low. Because
many pelvic serous cancers in mutation carriers are
believed to originate in the tubal fimbria [6,] it is particu-
larly concerning that 9% of operations left extra-uterine
fallopian tubes in situ. As expected, more recent year of
surgery was associated with more adequate surgery and
pathology reflecting improved knowledge of the surgeons
and pathologists over time.
Surgery performed by a specialised gynaecologic
oncologist was more likely to be adequate. This may reflect
greater awareness of the high cancer risk for these women
and the importance of complete removal of both ovaries
and tubes. Surgeries performed by gynaecologic oncolo-
gists were also more likely to be associated with adequate
pathology, possibly because gynaecologic oncologists are
more likely to practice within large teaching hospitals with
academic pathology departments performing better quality
examinations.
Only 23% of pathology reports documented that ovarian
and tubal tissues were embedded in toto. Ensuring all tissue
is embedded maximises the ability to detect microscopic
occult cancers and, because only the embedded tissue is
saved, it allows repeat examination of tissues at a later date
if required. Our result compares poorly with others in the
literature. In one recent multi-institutional study of RRSO
in BRCA1/2 mutation carriers, pathology reports from 385
women were centrally reviewed and 59% documented
embedding and examining the ovaries and fallopian tubes
in toto [37]. Two other smaller series reported full sec-
tioning of the ovaries and fallopian tubes in 74% [24] and
33% of women, respectively [18]. In the former series all
cases with full sectioning had surgery performed at one
specialised institution while none of the cases where sur-
gery was performed by outside institutions had full sec-
tioning performed [24]. The fact that surgical procedures in
Table 3 Characteristics of pathology
Characteristic n (%)
Clinical notes indicated high risk
Yes 151 (75)
No 37 (18)
Missing 13 (6)
Adequacy of pathological examination
Adequate 46 (23)
Not adequate 155 (77)
Extent of ovarian examination
Adequate (all tissue embedded) 65 (32)
Not adequatea 136 (68)
Extent of tubal examinationb
Adequate (all tissue embedded) 42 (22)
Not adequatea 149 (78)
Fimbria specifically examinedb
Yes 28 (15)
Not reported 163 (85)
Peritoneal washings cytology (n = 44)
Normal 43 (98)
Cancer 1 (2)
Occult cancer
‘‘Ovarian’’ 4 (2)
Endometrial 1 (0.5)
n number
a Only sections of tissue embedded or no documentation of what was
embedded
b n = 191 because 10 women had no fallopian tubes removed
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our study were performed at numerous centres across
Australia and New Zealand, each with a different pathol-
ogy laboratory, may have contributed to our result.
Four serous ovarian cancers, one endometrioid endo-
metrial cancer and no fallopian tube cancers were diag-
nosed at RRGS. Three of the serous ovarian cancers were
in BRCA1 mutation carriers. This is consistent with the
literature where the majority of reported occult carcinomas
arise in BRCA1 mutation carriers [18, 29, 38]. Our ‘‘occult
cancer’’ rate of 2% was at the lower end of the reported
range (0.6–18.5%) [9, 10, 18, 24, 26, 27, 29–31] but was
comparable to the 2.5% rate recently reported in a review
of 647 mutation carriers [37] and to the 0.6% rate from
another review of 175 mutation carriers [31]. Our apparent
low cancer rate may be a result of the majority of patients
having inadequate pathological examinations. Cancer
detection rates of 1–3% are reported for confirmed muta-
tion carriers in series without documentation of patholog-
ical technique [10, 39], but much higher rates of 10–26%
are reported when thorough pathological examination with
serial sectioning is mandated [16, 40]. For example, in one
series of 67 BRCA1/2 mutation carriers undergoing RRGS,
a protocol of complete removal and 2 mm serial sectioning
of both ovaries and fallopian tubes was the strongest pre-
dictor of occult cancer detection, and was more important
than age and mutation type [16].
Most pathology reports in this study did not document
the number of sections taken from each ovary and tube.
Pathology reports should be improved to include details of
how the tissue was processed and examined so that phy-
sicians caring for high risk women can be assured that
the tissue has been thoroughly examined. We believe a
Table 4 Predictors of adequate surgery
Characteristic Adequacy of surgery n (%) Univariable analysis Multivariable analysisa
Yes No Odds ratio (95% CI), P value Odds ratio (95% CI), P value
Age at RRGS (years)
30–39 24 (96) 1 (4) 1.95 (0.23–16.7), 0.5 2.09 (0.22–20.0), 0.5
40–49 86 (92) 7 (8) 1.00 1.00
50–59 49 (86) 8 (14) 0.50 (0.17–1.46), 0.2 0.55 (0.17–1.84), 0.3
C60 23 (90) 3 (10) 0.62 (0.15–2.60), 0.5 0.75 (0.14–3.93), 0.7
Trend (per year) 0.94 (0.89–0.99), 0.01 0.93 (0.87–0.99), 0.028
Year of RRGS
1998–2001 39 (83) 8 (17) 0.43 (0.16–1.16), 0.1 0.49 (0.16–1.55), 0.2
2002–2005 114 (92) 10 (8) 1.00 1.00
2006–2008 29 (97) 1 (3) 2.54 (0.31–20.7), 0.4 4.22 (0.46–38.7), 0.2
Trend (per year) 1.33 (1.08–1.64), 0.007 1.33 (1.07–1.67), 0.012
Type of surgeon
Gynaecologic oncologist 104 (98) 1 (2) 1.00 1.00
General Gynaecologist 71 (85) 14 (15) 0.05 (0.006-0.38), 0.004 0.05 (0.006-0.40), 0.005
General Surgeon 7 (64) 4 (36) 0.02 (0.002–0.17), 0.001 0.01 (0.001–0.13), \0.001
Type of Surgery
Abdominalb 58 (92) 5 (8) 1.00 1.00
Laparoscopic 124 (90) 14 (10) 0.76 (0.26–2.22), 0.6 0.89 (0.26–3.06), 0.8
BRCA1/2 carrier
No/untested 24 (88) 4 (12) 1.00 1.00
Yes 158 (91) 15 (9) 1.76 (0.54–5.73), 0.4 1.72 (0.42–7.09), 0.5
Prior invasive BC
No 79 (96) 4 (4) 1.00 1.00
Yes 103 (87) 15 (13) 0.18 (0.04–0.78), 0.02 0.24 (0.05–1.24), 0.09
C1 FDR with OC
No 125 (91) 13 (9) 1.00 1.00
Yes 57 (90) 6 (10) 0.99 (0.36–2.73), 0.9 1.61 (0.48–5.40), 0.4
RRGS risk-reducing gynaecological surgery, FDR first degree relative, BC breast cancer, OC ovarian cancer
a Adjusted for age (continuous), year of surgery (continuous) and type of surgeon (categorical), as appropriate
b Includes conversion from laparoscopic to abdominal
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standardised tissue processing and reporting protocol is
required to ensure all women have the same extent of
pathological examination and to ensure early stage malig-
nancies are not missed. Many ‘‘ovarian cancers’’ in muta-
tion carriers are now thought to originate in the tubal
fimbriae [41, 42] and pathologists must be made aware of
this to ensure the tubes and fimbria are fully embedded and
thoroughly sectioned and examined.
Although communication of high cancer risk from sur-
geon to pathologist was not an independent predictor of
adequate pathology, educating surgeons to include this
information on the pathology request form is still impor-
tant. Ovaries and fallopian tubes removed for reasons other
than cancer risk reduction do not require the same extent of
pathological evaluation. Without appropriate communica-
tion from the surgeon it is difficult for pathologists to
determine the specimens needing to be fully embedded and
thoroughly examined. It may also be helpful for surgeons
to request all tissue be embedded.
Despite our concern that microscopic cancers were
missed due to inadequate pathology, only one cancer was
diagnosed during follow up. This is consistent with the
rates of 1–3% reported in the literature following RRSO.
[10, 16, 31, 39] One explanation for this is that any cancers
not detected were of early stage and the risk-reducing
surgery alone was curative. If true, it could be argued that
complete pathological evaluation of removed tissues is of
academic interest only and is unlikely to change patient
outcomes. Alternatively, our follow-up time may be too
short for cancers to manifest. There is insufficient infor-
mation on the long term clinical consequences of early
pelvic serous cancers and further research is required.
Table 5 Predictors of adequate pathology
Characteristic Adequacy of pathology n (%) Univariable analysis Multivariable analysisa
Yes No Odds ratio (95% CI), P value Odds ratio (95% CI), P value
Age at RRGS (years)
30–39 2 (12) 23 (88) 0.18 (0.04–0.83), 0.03 0.21 (0.05–0.99), 0.05
40–49 30 (29) 63 (71) 1.00 1.00
50–59 11 (19) 46 (81) 0.50 (0.23–1.10), 0.09 0.52 (0.23–1.18), 0.1
C60 3 (13) 23 (87) 0.27 (0.08–0.98), 0.05 0.27 (0.07–1.03), 0.06
Trend (per year) 0.98 (0.94–1.02), 0.3 0.98 (0.94–1.02), 0.4
Year of RRGS
1998–2001 8 (15) 39 (85) 0.90 (0.37–2.18), 0.8 1.03 (0.41–2.58), 0.9
2002–2005 23 (18) 101 (82) 1.00 1.00
2006–2008 15 (50) 15 (50) 4.39 (1.88–10.2), 0.001 6.06 (2.38–15.4), \0.001
Trend (per year) 1.24 (1.06–1.45), 0.009 1.26 (1.06–1.49), 0.008
High risk on request form
No 6 (12) 31 (88) 1.00 1.00
Yes 40 (27) 111 (73) 1.86 (0.72–4.79), 0.2 1.60 (0.59–4.34), 0.4
Unknown 0 (0) 13 (100) – –
Type of surgeon
Gynaecologic oncologist 33 (31) 72 (69) 1.00 1.00
General gynaecologist 11 (12) 74 (88) 0.32 (0.15–0.69), 0.003 0.32 (0.15–0.70), 0.004
General surgeon 2 (18) 9 (82) 0.48 (0.10–2.37), 0.4 0.48 (0.10–2.41), 0.4
BRCA1/2 carrier
No/untested 10 (30) 18 (70) 1.00 1.00
Yes 36 (20) 137 (80) 0.47 (0.20–1.11), 0.09 0.49 (0.20–1.23), 0.1
Prior invasive BC
No 21 (25) 62 (75) 1.00 1.00
Yes 25 (20) 93 (80) 0.72 (0.37–1.40), 0.3 0.92 (0.44–1.90), 0.8
C1 FDR with OC
No 30 (21) 108 (79) 1.00 1.00
Yes 16 (24) 47 (76) 1.23 (0.61–2.46), 0.6 1.53 (0.72–3.22), 0.3
RRGS risk-reducing gynaecologic surgery, BC breast cancer, FDR first degree relative, OC ovarian cancer
a Adjusted for age (continuous), year of surgery (continuous) and type of surgeon (categorical), as appropriate
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Thorough pathological evaluation of removed tissue will
be important to gather information to enable such research.
Women in whom early cancers are detected should be
given the options of additional surgical staging, chemo-
therapy and closer follow-up. Important preventative and
therapeutic implications for the future could result from
detecting and studying these early cancers.
This study was multi-institutional and thus is likely a true
reflection of the management of high risk women in Aus-
tralia and New Zealand. However, the study has some lim-
itations. We relied on the information detailed in operation
and pathology reports to determine the adequacy of surgery
and pathology. If the operation report did not describe the
procedure in sufficient detail to determine what tissues were
removed, we assumed that the tissue received by the
pathologist represented the tissue removed by the surgeon. If
tissue was removed but not submitted for pathology review
we may have underestimated the number of adequate sur-
geries. We also assumed that ovarian and tubal tissue was not
fully embedded if the pathology report did not specifically
document this. It is possible that some specimens were
embedded in toto but not reported as such. This assumption
may have led to an underestimation of the rate of adequate
pathological examinations. However, our assumption that
tissue that was all embedded was also thoroughly sectioned
and examined may have caused us to overestimate the pro-
portion of specimens adequately examined.
Australasian BRCA1 and BRCA2 mutation carriers and
women at high familial risk of ‘‘ovarian’’ cancer who elect
RRSO must receive high quality care that will reduce their
risk of gynaecological cancer. This study highlights the
need for standardised surgical techniques and tissue pro-
cessing protocols for RRSO. Clinicians who discuss RRSO
with these women should consider referring them to spe-
cialist gynaecologic oncologists for their surgery, or at least
should discuss the specifics of optimal surgery and
pathology with the woman’s existing gynaecologist or
general surgeon if he/she is planning to undertake the
surgery. High risk women themselves should be educated
about the likely pathogenesis of pelvic serous cancers from
the fallopian tubes rather than the ovaries and hence the
type of surgery that is optimal. Using the term ‘‘ovarian
cancer’’ to describe this disease is misleading and arguably
should be abandoned to reflect the emerging evidence
regarding the pathogenesis of this disease.
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